2. Search Result
Search Result
Results for "

Beta+catenin+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

22

Inhibitors & Agonists

4

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10925
    Zolucatetide

    FOG-001; I-66

    		 β-catenin Cancer
    Zolucatetide (FOG-001;I-66) is a potent β-catenin inhibitor with an IC50 of <50 nM. Zolucatetide can inhibits β-catenin and T-cell factor (TCF) transcription factor interaction. Zolucatetide inhibits cell proliferation and induces cell cycle arrest in target cells. Zolucatetide exhibits anti-tumor efficacy in mice bearing COLO320DM colon cancer cell (with APC, TP53 mutations) xenografts. Zolucatetide can be used for the study of colon cancer .
    Zolucatetide
  • HY-13815
    KY02111
    5 Publications Verification

    		 Wnt Cardiovascular Disease
    KY02111 is a canonical WNT signaling (β-catenin) inhibitor which promotes differentiation of hPSCs to cardiomyocytes. KY02111 can be used for the research of human cardiomyocyte regeneration .
    KY02111
  • HY-P10925A
    (Z)-Zolucatetide

    (Z)-FOG-001; I-67

    		 β-catenin Cancer
    (Z)-Zolucatetide (I-67) is a β-catenin inhibitor with IC50 ≤50 nM. (Z)-Zolucatetide's sequence is Ac-PL3-Asp-Npg-B5-Asp-3COOHF-Aib-Ala-Phe-Lys3-PyrS2-3Thi-BztA-GlnR3-Ala-NH2. (Z)-Zolucatetide can be used for cancer research .
    (Z)-Zolucatetide
  • HY-101090
    KYA1797K
    Maximum Cited Publications
    17 Publications Verification

    		 Wnt β-catenin Cancer
    KYA1797K is a potent and selective Wnt/β-catenin inhibitor with an IC50 of 0.75 µM.
    KYA1797K
  • HY-122649
    UU-T01

    		β-catenin Cancer
    UU-T01 is a β-catenin inhibitor with a KD of 0.531 μM. UU-T01 binds to the K435, R469 and K508 residues of β-catenin, disrupting the β-catenin/TCF4 protein-protein interaction .
    UU-T01
  • HY-136464
    β-catenin-IN-2
    3 Publications Verification

    		 β-catenin Cancer
    β-catenin-IN-2 (Compound H1B1) is a potent β-catenin inhibitor. β-catenin-IN-2 can be used for the study of colorectal cancer .
    β-catenin-IN-2
  • HY-P5189A
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA

    		Endogenous Metabolite Cholinesterase (ChE) Others
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA, is a growth hormone releasing peptide, as well as a metabolite of GHRP-1. GHRP-1, or Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, has the effect of promoting the release of growth hormone (GH). GHRP-1 increases GH release and increases [Ca2+]i levels in static monolayer cells of rat pituitary gland, but does not affect cAMP levels .
    His-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2 TFA
  • HY-147007
    β-catenin-IN-3
    1 Publications Verification

    		 β-catenin Wnt CDK Cancer
    β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells .
    β-catenin-IN-3
  • HY-147651
    β-catenin-IN-4

    		β-catenin CDK c-Myc Cancer
    β-catenin-IN-4 (Compound 39) is a β-catenin inhibitor with a Ki of 0.64 μM. β-catenin-IN-4 reduces the protein expression levels of cyclin D1 and c-Myc .
    β-catenin-IN-4
  • HY-160488
    PTK7/β-catenin-IN-1

    		β-catenin Cancer
    PTK7/β-catenin-IN-1 (compound 01065) is a potent PTK7/β-catenin inhibitor with an IC50 of 8.9 μM and 56.5 μM for PTK7/β-catenin and p53/MDM2, respectively. PTK7/β-catenin-IN-1 has the potential for cancer research .
    PTK7/β-catenin-IN-1
  • HY-173482
    TFAP4/Wnt/β-catenin-IN-1

    		Wnt β-catenin Cancer
    TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active TFAP4/Wnt/β-catenin inhibitor. TFAP4/Wnt/β-catenin-IN-1 has significant anticancer activity against a variety of cancer cells (such as gastric cancer, lung cancer, breast cancer, etc.), and has the strongest anticancer activity against MGC-803 gastric cancer cells (IC50: 3.92 μM). TFAP4/Wnt/β-catenin-IN-1 induces apoptosis and cell cycle arrest (S phase) in cancer cells by inhibiting the TFAP4/Wnt/β-catenin signaling pathway. TFAP4/Wnt/β-catenin-IN-1 can be used in the study of gastric cancer .
    TFAP4/Wnt/β-catenin-IN-1
  • HY-179408
    β-catenin-IN-9

    		β-catenin Apoptosis Cancer
    β-catenin-IN-9 is a β-catenin inhibitor. β-catenin-IN-9 induces apoptosis, cell cycle arrest, and inhibits migration, invasion, and epithelial-mesenchymal transition (EMT) in colorectal cancer cells. β-catenin-IN-9 suppresses the transcription of β-catenin and vimentin, and significantly inhibits β-catenin at the protein level. β-catenin-IN-9 can be used for the research of colorectal cancer .
    β-catenin-IN-9
  • HY-133179
    Wnt/β-catenin-IN-4

    		Wnt Metabolic Disease
    Wnt/β-catenin-IN-4 (compound YW1159) is a potent Wnt/β-catenin inhibitor .
    Wnt/β-catenin-IN-4
  • HY-10834
    β-catenin-IN-6

    		β-catenin Cancer
    β-catenin-IN-6 is a β-catenin inhibitor, targeting to canonical Wingless-related integration site signaling pathway. β-catenin-IN-6 inhibits human colorectal cancer cells proliferation, as well as in a β-catenin/RK3E mouse model .
    β-catenin-IN-6
  • HY-149858
    β-catenin-IN-7

    		Wnt Cancer
    β-catenin-IN-7 (Compound 9) is a β-catenin inhibitor. β-catenin-IN-7 inhibits the interaction between β-catenin and Tcf-4, and inhibits Wnt-dependent target gene expression. β-catenin-IN-7 has anti-cancer activity .
    β-catenin-IN-7
  • HY-169348
    β-catenin-IN-8

    		β-catenin Wnt c-Myc Cancer
    β-catenin-IN-8 (Compound 25) is a β-catenin inhibitor. β-catenin-IN-8 inhibits β-catenin and c-Myc protein levels, and inhibits Wnt-target genes level (Fgf20 and Sall4). β-catenin-IN-8 has colorectal cancer anticancer activities, and has metabolic stability .
    β-catenin-IN-8
  • HY-158210
    Wnt/β-catenin-IN-3

    		Wnt β-catenin MDM-2/p53 Cancer
    Wnt/β-catenin-IN-3 (compound 17) is a Wnt/β-catenin inhibitor with low micromolarGI50s against various cancer cells. Wnt/β-catenin-IN-3triggers G2/M cell cycle arrest though activation of p53-p21 pathway as well as intrinsic and extrinsic apoptotic death of colon cancer cells .
    Wnt/β-catenin-IN-3
  • HY-133180
    YW1128

    		Wnt β-catenin Metabolic Disease
    YW1128 (compound 3a) is a potent Wnt/β-Catenin inhibitor. YW1128 induces the proteasome degradation of β-catenin and subsequent inhibits the Wnt/β-catenin signaling in cells. YW1128 significantly decreases hepatic lipid accumulation. YW1128 improves glucose tolerance of high fat diet-fed mice without noticeable toxicity. YW1128 down regulates the genes involved in the glucose and fatty acid anabolism .
    YW1128
  • HY-164520
    PMED-1

    		Wnt Cancer
    PMED-1 is a β-catenin inhibitor that significantly reduces β-catenin activity in hepatoblastoma cells and various HCC cells, with an IC50 value ranging from 4.87 to 32 μM. PMED-1 affects Wnt signaling by decreasing the interaction between β-catenin and CREB binding protein, thereby inhibiting cell proliferation. PMED-1 has potential applications in cancer research .
    PMED-1
  • HY-P11597
    Getacatetide

    CY-101

    		 Wnt β-catenin Cancer
    Getacatetide (CY-101) is a peptide-based Wnt/β-catenin inhibitor, which can be used for the study of solid tumors .
    Getacatetide
  • HY-101090R
    KYA1797K (Standard)

    		Wnt Reference Standards β-catenin Cancer
    KYA1797K (Standard) is the analytical standard of KYA1797K (HY-101090). This product is intended for research and analytical applications. KYA1797K is a potent and selective Wnt/β-catenin inhibitor with an IC50 of 0.75 µM.
    KYA1797K (Standard)
  • HY-10834R
    β-catenin-IN-6 (Standard)

    		Reference Standards β-catenin Cancer
    β-catenin-IN-6 (Standard) is the analytical standard of β-catenin-IN-6 (HY-10834). This product is intended for research and analytical applications. β-catenin-IN-6 is a β-catenin inhibitor, targeting to canonical Wingless-related integration site signaling pathway. β-catenin-IN-6 inhibits human colorectal cancer cells proliferation, as well as in a β-catenin/RK3E mouse model .
    β-catenin-IN-6 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: